FindMyRecallSubscribe
Class I: serious health riskTerminated

Performance Plus Marketing libigrow XXXTREME Capsules Recall

libigrow XXXTREME Capsules, MAXIMUM STRENGTH FORMULA, 1000 mg, supplied in 1, 5 and 10…

Performance Plus Marketing, Inc. · Commerce, CA

Risk level
Class I
Reported by FDA
May 22, 2013
Recall ID
D-333-2013
Check your lot numberHow we source this data

Summary

Performance Plus Marketing recalled libigrow XXXTREME Capsules starting Dec 17, 2012. The FDA classified it as Class I (serious health risk) and published enforcement report D-333-2013 on May 22, 2013. Reason: Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs. Status: Terminated.

Why it was recalled

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Product description

libigrow XXXTREME Capsules, MAXIMUM STRENGTH FORMULA, 1000 mg, supplied in 1, 5 and 10 count blister packs, Distributed By Kretek International, Inc. Moorpark, CA 930210 1 count blister: UPC 705105830735, 5 count blister: UPC 610585435939, 10 count blister: UPC 610585435922.

Lot numbers, UPCs & expiration codes

1 count blister: Lot# 01MNU0912, Exp: 09/15; Lot# 01X0412-1, Exp: 04/15; Lot# 021647, Exp: 12/13, 5 count blister: Lot# 05X0412, Exp: 04/16, 10 count blister: Lot# 10X0412, Exp: 04/16; Lot# 10M0111, Exp: 01/14.

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-333-2013
Classification
Class I
Status
Terminated
Recall initiated
Dec 17, 2012
FDA report date
May 22, 2013
Quantity
686,000 capsules
Recall type
Voluntary: Firm initiated
Recalling firm
Performance Plus Marketing, Inc.

Original FDA data

Every field from FDA enforcement report D-333-2013, exactly as published.

Show all FDA fields
City
Commerce
State
CA
Status
Terminated
Country
United States
Event ID
63916
Address
5560 E 61st St
Code information
1 count blister: Lot# 01MNU0912, Exp: 09/15; Lot# 01X0412-1, Exp: 04/15; Lot# 021647, Exp: 12/13, 5 count blister: Lot# 05X0412, Exp: 04/16, 10 count blister: Lot# 10X0412, Exp: 04/16; Lot# 10M0111, Exp: 01/14.
Postal code
90040-3406
Report date
May 22, 2013
Product type
Drugs
Recall number
D-333-2013
Classification
Class I
Recalling firm
Performance Plus Marketing, Inc.
Product quantity
686,000 capsules
Termination date
Nov 14, 2013
Reason for recall
Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs
Voluntary / mandated
Voluntary: Firm initiated
Product description
libigrow XXXTREME Capsules, MAXIMUM STRENGTH FORMULA, 1000 mg, supplied in 1, 5 and 10 count blister packs, Distributed By Kretek International, Inc. Moorpark, CA 930210 1 count blister: UPC 705105830735, 5 count blister: UPC 610585435939, 10 count blister: UPC 610585435922.
Distribution pattern
Nationwide
Recall initiation date
Dec 17, 2012
Initial firm notification
Telephone
Center classification date
May 16, 2013

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-333-2013, published May 22, 2013. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls